Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.

Annette WundesSibyl WrayRalf GoldBarry A SingerElzbieta JasinskaTjalf ZiemssenJerome de SezePavle RepovicHailu ChenJerome HannaJordan Messer Catherine MillerRobert T Naismith

Published in: Therapeutic advances in neurological disorders (2021)

[ClinicalTrials.gov identifier: NCT03093324].

Keyphrases

phase iii
double blind
placebo controlled
open label
clinical trial
phase ii
mass spectrometry
multiple sclerosis
study protocol
randomized controlled trial